Curative Biotechnology, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CUBT research report →
Price Chart
About the company
Curative Biotechnology, Inc. is an emerging biomedical firm primarily focused on developing pharmaceutical products. Its research and development efforts are concentrated on a diverse pipeline targeting critical therapeutic areas, including infectious diseases, cancer, and vision-impairing degenerative eye conditions.
- CEO
- I. Richard Garr
- IPO
- 1998
- Employees
- 4
- HQ
- Palm Beach Gardens, FL, US
Get TickerSpark's AI analysis on CUBT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $5.12M
- P/E
- -1.85
- PEG
- -0.06
- P/S
- 0.00
- P/B
- -0.97
- EV/EBITDA
- -5.53
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 33.00%
- ROIC
- 24.46%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-87,843+4.7%
- Op Income
- $-1,502,061
- Net Income
- $-2,263,073+36.5%
- EPS
- $-0.00+99.5%
- OCF Growth
- +15.0%
- FCF Growth
- +15.0%
- 52W High
- $1.99
- 52W Low
- $0.03
- 50D MA
- $0.99
- 200D MA
- $1.11
- Beta
- 1.30
- RSI (14)
- 43
- Avg Volume
- 736
No earnings-call transcripts are available for CUBT yet.
- Free Float
- 19.9%
- Shares Outstanding
- 6.82M
- Float Shares
- 1.36M
Our CUBT coverage
Recent articles, reports, and earnings notes.
No research on CUBT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CUBT report →Curative Biotechnology, Inc. Issues Letter to Shareholders
globenewswire.com · Sep 11
Curative Biotechnology Advances Translational Ophthalmology Program Through PennVet Research Agreement
globenewswire.com · May 7
Curative Biotechnology Announces Reverse Stock Split and Strategic Progress Toward OTCQB Uplisting
globenewswire.com · Mar 23
Curative Biotechnology Announces Reverse Stock Split and Strategic Progress Toward OTCQB Uplisting
globenewswire.com · Mar 23
Curative Biotechnology Announces Canadian Patent Allowance
globenewswire.com · Jan 23
Curative Biotechnology, Inc. Announces Letter to Shareholders
globenewswire.com · Nov 18
Curative Biotechnology, Inc. Engages Golden Eagle Capital Advisors, Inc. as Exclusive Agent and Strategic Advisor
globenewswire.com · Dec 13
Curative Biotechnology, Inc. Announces Nomination of Dr.
headlinesoftoday.com · Mar 31
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.